OBJECTIVE: Lung cancer is often diagnosed at an advanced stage and survival has been poor, although long-term studies have been rare. We analyzed data on survival in lung cancer from Denmark, Finland, Norway, and Sweden over a 50-year period (1971-2020). METHODS: Relative 1- and 5-year survival data were obtained from the NORDCAN database for 1971-2020. We used generalized additive models to estimate survival trends over time and uncertainty of these estimates. We additionally calculated conditional survival from the 1st to 5th year (5/1-year), estimated annual changes in survival rates, and determined significant breaking points. RESULTS: In 2016-2020, 5-year survival rate for lung cancer was best for Norwegian men (26.6%) and women (33.2%). The sex difference was significant and it was found for each country. Survival improved modestly until the year 2000, after which time survival curves increased steeply and kept the linear shape to the end of follow-up, indicating consistent improvement in survival. Survival curves for 1- and 5/1-year survival were almost superimposable, indicating that deaths in the first year were approximately as many as in the subsequent 4 years, thus marking sustained long-term survival. CONCLUSION: We could document a positive development in lung cancer survival with steep upward trends after the year 2000. Intensions for curative treatment have been increasing and the outcomes have been improving with the help of novel imaging methods. Pathways for facile patient access to treatment have been instituted. Close to 90% of the patients are ever smokers. National anti-smoking acts and alerting people who smoke about early symptoms may be beneficial, as metastatic lung cancer remains difficult to cure.

Biomedical Center Faculty of Medicine Charles University Pilsen Pilsen 30605 Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Department of Urology Helsinki University Hospital Helsinki Finland

Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Germany

Institute of Pathological Physiology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Polednak A. Trends in cancer incidence in Connecticut, 1935–1991. Cancer. 1994;74:2863–2872. doi:10.1002/1097-0142(19941115)74:10<2863::AID-CNCR2820741020>3.0.CO;2-5 PubMed DOI

Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995;103(Suppl8):131–142. doi:10.1289/ehp.95103s8131 PubMed DOI PMC

Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21(2):96–101. doi:10.1136/tobaccocontrol-2011-050294 PubMed DOI

Lipfert FW, Wyzga RE. Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis. Crit Rev Toxicol. 2019;49(9):790–818. doi:10.1080/10408444.2019.1700210 PubMed DOI

IARC. Personal Habits and Indoor Combustions. Lyon: International Agency for Research on Cancer; 2012:575.

Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime smoking history and risk of lung cancer: results from the Framingham heart study. J Natl Cancer Inst. 2018;110(11):1201–1207. doi:10.1093/jnci/djy041 PubMed DOI PMC

Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS One. 2022;17(1):e0261124. doi:10.1371/journal.pone.0261124 PubMed DOI PMC

Patja K, Hakala SM, Boström G, Nordgren P, Haglund M. Trends of tobacco use in Sweden and Finland: do differences in tobacco policy relate to tobacco use? Scand J Public Health. 2009;37(2):153–160. doi:10.1177/1403494808100277 PubMed DOI

Collaborators G. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885–1906. doi:10.1016/S0140-6736(17)30819-X PubMed DOI PMC

Park SY, Lee JG, Kim J, et al. The influence of smoking intensity on the clinicopathologic features and survival of patients with surgically treated non-small cell lung cancer. Lung Cancer. 2013;81(3):480–486. doi:10.1016/j.lungcan.2013.07.002 PubMed DOI

Okamoto T, Suzuki Y, Fujishita T, et al. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer--differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer. 2014;85(2):125–130. doi:10.1016/j.lungcan.2014.06.006 PubMed DOI

Bergman M, Fountoukidis G, Smith D, Ahlgren J, Lambe M, Valachis A. Effect of smoking on treatment efficacy and toxicity in patients with cancer: a systematic review and meta-analysis. Cancers. 2022;14:17. doi:10.3390/cancers14174117 PubMed DOI PMC

Turner MC, Andersen ZJ, Baccarelli A, et al. Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations. CA Cancer J Clin. 2020;70(6):460–479. doi:10.3322/caac.21632 PubMed DOI PMC

Frank C, Fallah M, Ji J, Sundquist J, Hemminki K. The population impact of familial cancer, a major cause of cancer. Int J Cancer. 2014;134:1899–1906. doi:10.1002/ijc.28510 PubMed DOI

Liu X, Hemminki K, Forsti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137:903–910. PubMed

Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi:10.1016/j.eururo.2018.09.001 PubMed DOI

Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–1141. doi:10.1038/s41416-018-0029-6 PubMed DOI PMC

Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ. 2005;330(7485):223. doi:10.1136/bmj.38308.477650.63 PubMed DOI PMC

Lorenzo-Gonzalez M, Ruano-Ravina A, Torres-Duran M, et al. Lung cancer risk and residential radon exposure: a pooling of case-control studies in northwestern Spain. Environ Res. 2020;189:109968. doi:10.1016/j.envres.2020.109968 PubMed DOI

Engholm G, Ferlay J, Christensen N, et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–736. doi:10.3109/02841861003782017 PubMed DOI

Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455. doi:10.1080/0284186X.2017.1407039 PubMed DOI

Larønningen S, Ferlay J, Beydogan H, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries. Association of the Nordic cancer registries. Cancer Registry of Norway; 2022.

Lundberg FE, Andersson TM, Lambe M, et al. Trends in cancer survival in the Nordic countries 1990–2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266–1274. doi:10.1080/0284186X.2020.1822544 PubMed DOI

Tichanek F, Försti A, Liska V, Hemminki A, Hemminki K. Survival in colon, rectal and small intestinal cancers in the Nordic countries through a half century. Cancers. 2023;15:3. doi:10.3390/cancers15030991 PubMed DOI PMC

Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77–85. doi:10.1016/j.ejca.2022.08.015 PubMed DOI

Sachs E, Sartipy U, Jackson V. Sex and survival after surgery for lung cancer: a Swedish nationwide cohort. Chest. 2021;159(5):2029–2039. doi:10.1016/j.chest.2020.11.010 PubMed DOI PMC

Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Møller B. Lung cancer survival in Norway, 1997–2011: from nihilism to optimism. Eur Respir J. 2016;47(1):275–287. doi:10.1183/13993003.00650-2015 PubMed DOI

Löfling L, Bahmanyar S, Kieler H, Lambe M, Wagenius G. Temporal trends in lung cancer survival: a population-based study. Acta Oncol. 2022;61(5):625–631. doi:10.1080/0284186X.2021.2013529 PubMed DOI

Leskelä RL, Peltonen E, Haavisto I, et al. Trends in treatment of non-small cell lung cancer in Finland 2014–2019. Acta Oncol. 2022;61(5):641–648. doi:10.1080/0284186X.2022.2042474 PubMed DOI

Solberg S, Nilssen Y, Brustugun OT, et al. Increase in curative treatment and survival of lung cancer in Norway 2001–2016. Eur J Epidemiol. 2019;34(10):951–955. doi:10.1007/s10654-019-00536-z PubMed DOI

Borg M, Hilberg O, Andersen MB, Weinreich UM, Rasmussen TR. Increased use of computed tomography in Denmark: stage shift toward early stage lung cancer through incidental findings. Acta Oncol. 2022;61(10):1256–1262. doi:10.1080/0284186X.2022.2135134 PubMed DOI

Maconachie R, Mercer T, Navani N, McVeigh G. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019;364:1049. doi:10.1136/bmj.l1049 PubMed DOI

Sørensen JB, Horvat P, Rosenlund M, et al. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study. Future Oncol. 2022;18(2):205–214. doi:10.2217/fon-2021-0746 PubMed DOI

Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians--a national Danish project. Health Policy. 2012;105(1):65–70. doi:10.1016/j.healthpol.2011.11.001 PubMed DOI

Hemminki K, Försti A, Hemminki O, Liska V, Hemminki A. Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries. JHEP Rep. 2022;4(12):100602. doi:10.1016/j.jhepr.2022.100602 PubMed DOI PMC

Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. Eur J Cancer Prev. 2022;31(3):228–234. doi:10.1097/CEJ.0000000000000694 PubMed DOI

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (Concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi:10.1016/S0140-6736(17)33326-3 PubMed DOI PMC

Lundberg FE, Birgisson H, Johannesen TB, et al. Survival trends in patients diagnosed with colon and rectal cancer in the Nordic countries 1990–2016: the NORDCAN survival studies. Eur J Cancer. 2022;172:76–84. doi:10.1016/j.ejca.2022.05.032 PubMed DOI

Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers